Celgene Thalomid Tardy Adverse Event Reporting Cited By FDA
Executive Summary
Celgene has retained a new firm to handle adverse drug reports for Thalomid (thalidomide) following FDA criticisms about delayed reports for the drug
You may also be interested in...
Managing Risk Management: FDA Wants To Gauge Effectiveness Of RiskMAPs
FDA should evaluate the effectiveness of risk management plans, Office of Pharmacoepidemiology & Statistical Science Director Paul Seligman said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011